Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal > distal muscle weakness and paralysis. SMA is classified into 4 phenotypes based on the age of onset and the highest physical milestone achieved:

– SMA type I

– SMA type II

– SMA type III

– SMA type IV

Stem cells can help SMA patients through neuro-protective and neuro-regenerative effects. Stem cell transplantation through the Regentime procedure can replenish the motor neuron pool and potentially form functional neuromuscular connections. In addition, transplanted stem cells secrete neurotrophic factors that can protect existing motor neurons from degeneration.

The Regentime procedure for SMA requires a stay of 5 days in Lebanon, with prices ranging from 27,300 USD to 38,600 USD.